陳誌龍：二級教授、博士生導師🤹🏼♀️。
為第二軍醫大學藥學學士🏄🏿♂️🏌🏻♀️、醫學博士（藥學專業）🤾🏽♂️，曾先後在中科院上海有機化學研究所、澳大利亞Central Queensland University👎、英國The University of Liverpool進行博士後研究。曾任第二軍醫大學防護醫學教研室主任、學科帶頭人。現為沐鸣2生物醫藥研究組課題組長🤿，PI，藥物化學與藥理學教授，博士生導師👰🏻。
為中國光學會激光醫學分會常務理事；上海藥學會理事🏂🏿；上海生化藥物專業委員會副主任委員；上海藥物化學專業委員會委員📂；上海藥學會產學研創新工作委員會委員🧑🏼🎓🌗；上海市藥學會醫院藥學專委會委員；上海藥理學會治療藥物監測研究專委會委員💂🏽♂️；上海市抗癌協會腫瘤藥學專委會委員🖕🏿；上海市醫院協會臨床藥事管理專委會委員；上海市醫學會第六屆醫療事故鑒定專家庫成員👩🏻🦽➡️👩🏽🦰；上海市醫學會第四屆預防接種異常反應鑒定專家庫成員。
為國家科學技術獎勵評審專家；科技部重大重點專項評審專家；國家自然科學基金評審專家；教育部計劃項目與博士點基金評審專家；上海市科委項目評審專家💂🏼♂️👳🏿。
發表論文340余篇。出版英文專著2部🤪、中文專著3部。申請國家發明專利90余項。
研究方向:
（1）人工智能(AI)和計算機輔助 (CADD)新藥研發🤚；
（2）光敏新藥研發及光動力療法的基礎與應用研究（如抗腫瘤🚜、抗鮮紅斑痣、抗類風濕性關節炎🧑🏼🦲🧑🏿🎄、抗菌抗病毒作用等）；
（3）靶向藥物研究（如抗腫瘤靶向新藥研究➕；降壓新藥研究；葉酸、多肽、單克隆抗體等靶向分子導向的新藥研究）；
（4）多功能👻🏃🏻♂️、多模態藥物納米靶向製劑研究👊🏿；
（5）中藥與天然藥物研究；
（6）藥物代謝、藥理毒理學及臨床藥學研究。
（7）醫學成像試劑研究。
主要研究成果：
（1）在光敏新藥研製及光動力療法基礎與應用研究領域做出了出色成績，處於國內領先🍮，國際上有一定影響力🏄🏽♀️。有2個光敏新藥進入臨床研究，1個進行臨床前研究🧑🏽🦲。
（2）創製了1個高效、長效、低毒的沙坦類降壓新藥，正在進行臨床前研究🕕。
（3）作為主要成員參與研發的國家一類抗腫瘤新藥CM-Na已獲準上市（該項目獲國家發明二等獎）、光敏新藥血卟啉單甲醚已獲準上市。
（4）發現了一個新的有機化學反應--三聯吡啶的重排反應，該反應在製備具有特殊光化學與光生物醫學性能的三聯吡啶化合物及其金屬配合物領域具有重要用途🧘🏻♀️。
（5）在藥物納米靶向傳遞劑型研究領域🫚，在新藥藥理評價模型構建、新藥評價方法研究等領域也做出了一定成績。
（6）在新藥仿製與醫藥中間體製備工藝研究領域做出了出色成績。茶堿類系列產品🧎🏻♀️➡️、氨基葡萄糖系列產品在企業實現產業化，產值過億元。
榮譽及獲獎情況🧑🏽🚒：
1、第二軍醫大學 “學習成才十佳先進個人”🧔🏽♀️；
2、上海市“浦江人才”；
3🕥、南京市“創新創業人才”🧵；
4🔘、上海市“優秀學術技術帶頭人”；
5🧙🏿♀️、嘉興市“科技領軍人才”
6👐🏿、主持項目“光敏新藥與試劑的研製及光動力療法的基礎與應用研究”獲上海市藥學科技二等獎（2012年）♡。
7👩🏻🎨、主持項目“光敏新藥與試劑的研製及光動力療法的基礎與應用研究”獲中國藥學科技三等獎（2013年）🎉。
8、參與項目（第二負責人）“光動力治療皮膚病關鍵技術創新及推廣應用”獲中華醫學科技三等獎（2017年）。
9、主持，平湖市創新創業大賽一等獎----光敏新藥與試劑及降壓新藥研究開發（2018年）。
承擔的項目：
承擔各類項目90余項，其中主持50余項，參與30余項。如主持各類人才基金5項🧒🏽、國家自然科學基金6項、軍隊醫藥衛生重大課題1項💺👩🏽🔬、上海市科委與教委重點項目7項😪、國際合作項目8項等⚡️🧎♂️。參與國家與國際重要課題6項🤸🏿，如國家新藥創製重大專項👩🦲、國家自然科學基金重點項目等🙆🏽♀️；指導團隊成員獲國家自然基金5項、國家與上海市博士後基金11項、上海市科委重點項目8項等。部分課題如下：
1😮、國家自然科學基金（編號：21372042；30973611；30271534；30070862；29872055；21977016等）⚪️👨🏻🦼➡️。
2、上海市優秀學術技術帶頭人人才計劃基金（編號：15XD1523400）。
3💞、上海市浦江人才計劃基金（編號🦡：06PJ14001）☝️。
4🏋🏻、上海市科委重大重點基金（編號🚞：13431900700；15411960400；14140903500🏊🏼；17431902600；14431906200🪈；15431904100；21430730100等）。
5、科技部與上海市國際科技合作基金（編號🍋：6-11🙎🏻♀️🙋♀️、11BA1400700、13430722300🧜🏿、17430711900、17430741800、18430713000🦅、20490740400、21430730100等）。
6👱🏿♂️、軍隊醫藥衛生重大項目（編號01L054）🔔。
7🫥、上海市教委重點項目基金（編號🧑🏼🔧：10ZZ45）。
發表論文：發表論文340余篇🔷，部分論文如下：
1. Tabbisa Namulinda, Zhi-Long Chen*, et al. Antibacterial and anticancer activities of green synthesized silver nanoparticles using Photinia glabra fruit extract. Nanomedicine, 2023, 18, (14): 987-1002. (SCI, Q1)
2. Man Yi Li, Zhi Long Chen*, et al. The bromoporphyrins as promising anti-tumor photosensitizers in vitro. Photochemical & Photobiological Sciences, 2023, 22, 427-439. (SCI, Q2)
3. Man Yi Li, Zhi Long Chen*, et al, The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2335-2346. (SCI, Q2)
4. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new fluorinated pyropheophorbide-a derivatives for photodynamic therapy. Dyes and Pigments, 2022, 197, 109932.(SCI, Q1,TOP期刊)
5. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new pyropheophorbide-a derivatives for CAIX-targeted photodynamic therapy. Dyes and Pigments, 2022, 203,110328.(SCI, Q1, TOP期刊).
6. Faiza Sajjad, Zhi-Long Chen*, et al. Incorporation of green emission polymer dots into pyropheophorbide-α enhance the PDT effect and biocompatibility. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102562.（SCI, Q3）
7. Man-Yi Li, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of novel fluorinated hematoporphyrin ether derivatives for photodynamic therapy. Bioorganic Chemistry, 2021, 107, 104528.(SCI, Q1,TOP期刊)
8. Faiza Sajjad, Zhi-Long Chen*, et al. Synthesis and invitro PDT evaluation of red emission polymer dots (R-CPDs) and pyropheophorbide-α conjugates. Scientific Reports. 2021, 11, 10013. (SCI, Q2)
9. Zhuo Wu, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities. Bioorganic Chemistry, 2020, 101, 104042. (SCI, Q1,TOP期刊)
10.Ying-Hua Gao, Zhi-Long Chen*. Synthesis and pharmacological evaluation of chlorin derivatives for photodynamic therapy of cholangiocarcinoma. European Journal of Medicinal Chemistry, 2020,189, 112049.(SCI, Q1,TOP期刊)
11. Ying-Hua Gao, Zhi-Long Chen*, Synthesis and evaluation of novel chlorophyll a derivatives as potent photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2020, 187, 111959.(SCI, Q1,TOP期刊)
12.Ying-Hua Gao, Vanda Lovreković, Zhi-Long Chen*, et al. The photodynamic activities of dimethyl 131-[2-(guanidinyl)ethylamino] chlorin e6 photosensitizers in A549 tumor. European Journal of Medicinal Chemistry, 2019, 177, 144-152. (SCI, Q1,TOP期刊)
13. Zhuo Wu, Yi-Jia Yan, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of AT1 receptor blockers derived from 6-substituted aminocarbonyl benzimidazoles. European Journal of Medicinal Chemistry, 2019,181,111553. (SCI, Q1,TOP期刊)
14. Zhuo Wu, Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of 6-benzoxazole benzimidazole derivatives with anti-hypertension activities. ACS Medicinal Chemistry Letters, 2019, 10, 40 - 43. (SCI, Q2)
15. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity. European Journal of Medicinal Chemistry, 2018, 160, 146-156. (SCI, Q1,TOP期刊)
16. Sonja Srdanovic, Davor Margetic*, Zhi-Long Chen*. The photodynamic activity of 131-[2’-(2-pyridyl)ethylamine] chlorin e6 photosensitizer in human esophageal cancer. Bioorganic & Medicinal Chemistry Letters. 2018, 28(10): 1785-1791. (SCI, Q2)
17. Wei Zhu, Yi-Jia Yan, Zhi-Long Chen*, et al. Synthesis and biological evaluation of 173-dicarboxylethyl pyropheophorbide-a amide derivatives for photodynamic therapy. Bioorganic & Medicinal Chemistry Letters. 2018, 28: 2784-2788. (SCI, Q2)
18. Ping-Yong Liao, Zhi-Long Chen*, et al. Synthesis of 2-morpholinetetraphenylporphyrins and their photodynamic activities. Bioorganic Chemistry, 2017, 71: 299 - 304.(SCI, Q1,TOP期刊)
19. Li Wang, Wei Zhu, Zhi-Long Chen*, et al. Preparation of a chlorophyll derivative and investigation of its photodynamic activities against cholangiocarcinoma. Biomedicine & Pharmacotherapy. 2017, 92: 285-292. (SCI, Q1,TOP期刊)
20. Lei-Lei Bao, Donal F. O’Shea*, Zhi-Long Chen*, et al. In vitro and in vivo evaluation of a pyropheophorbide-a derivative as a potential photosensitizer for age-related macular degeneration. Biomedicine & Pharmacotherapy, 2017, 88: 1220-1226. (SCI, Q1,TOP期刊)
21.Xiaolu Bao, Weibo Zhu, Zhilong Chen*, et al. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists. European Journal of Medicinal Chemistry, 2016, 123,115-127.(SCI, Q1,TOP期刊)
22. Weibo Zhu, Xiaolu Bao, Zhilong Chen*, et al. N-phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2016, 115,161-178.(SCI, Q1,TOP期刊)
23. Xiang-Hua Zhang, Li-Jun Zhang, Zhi-Long Chen*, et al. Photodynamic efficiency of a chlorophyll-a derivative in vitro and in vivo. Biomedicine & Pharmacotherapy, 2016, 81, 265-272. (SCI, Q1,TOP期刊)
24. Li-Jun Zhang, Yi-Jia Yan, Zhi-Long Chen*, et al. Antitumor activity evaluation of meso-tetra (pyrrolidine substituted) pentylporphin-mediated photodynamic therapy in vitro and in vivo. Journal of Photochemistry & Photobiology, B: Biology. 2016, 163:224-231. (SCI, Q1,TOP期刊)
25. Ping-Yong Liao, Ying-Hua Gao, Zhi-Long Chen*, et al. Tetraphenylporphyrin derivatives possessing piperidine group as potential agents for photodynamic therapy. Journal of Photochemistry & Photobiology, B: Biology. 2016, 165: 213-219. (SCI, Q1)
26. Hongyu Tan, Ioannis Houpis, Zhilong Chen*, et al. Olefin preparation via palladium-catalyzed oxidative de-azotative and de-sulfitative internal cross-coupling of sulfonylhydrazones. Organic Letters, 2015,17(14)🏆：3548-3551.(SCI, Q1,TOP期刊)
27. Dan Wu, Zhi-Long Chen and Donal F. O’Shea, et al. Synthesis and assessment of a maleimide functionalized BF2 azadipyrromethene near-infrared fluorochrome. Chemical Communications, 2015, 51(93): 16667-16670.(SCI, Q1,TOP期刊)
28. Li-Jun Zhang, Zhi-Long Chen*, et al. Evaluation of a bacteriochlorin-based photosensitizer’s anti-tumor effect in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2015, 141（11）: 1921-1930. (SCI, Q2)
29. Hongyu Tan, Zhilong Chen*, et al. Palladium-catalyzed coupling of sulfonylhydrazones with heteroaromatic 2-amino-halides (Barluenga Reaction): exploring the electronics of the sulfonylhydrazone. Organic Process Research & Development. 2015, 19(8), 1044-1048. (SCI, Q1)
30. Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and evaluation of novel angiotensin II receptor 1 antagonists with antihypertensive activities. RSC Advances, 2017, 7: 26401-26410. (SCI, Q2)
31. Pingyong Liao, Zhilong Chen*, et al. Synthesis, characterization and biological evaluation of a novel biscarboxymethyl-modified tetraphenylchlorin compound for photodynamic therapy. RSC Advances, 2016, 6: 26186 - 26191. (SCI, Q2)
32. Mengshi Yang, Zhilong Chen, et al. Photodynamic therapy of drug-resistant human colon adenocarcinoma using verteporfin loaded TPGS nanoparticle with tumor homing and penetrating peptide functionalized. RSC Advances, 2016, 6: 100984-100992. (SCI, Q2)
33.Dan Wu, Zhi-long Chen, et al. Strained alkyne substituted near infrared BF2 azadipyrromethene fluorochrome. RSC Advances, 2016, 6: 87373-87379. (SCI, Q2)
34. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of new 5-aminolevulinic acid derivatives as prodrugs of protoporphyrin for photodynamic therapy. Photochemical & Photobiological Sciences. 2017, 16: 1623-1630. (SCI, Q2)
35. Ping-Yong Liao, Xinrong Wang, Zhi-Long Chen*, et al. Synthesis, photophysical properties and biological evaluation of b-alkylaminoporphyrin for photodynamic therapy. Bioorganic & Medicinal Chemistry, 2016, 24(22): 6040-6047. (SCI, Q2)
36. Xiaolu Bao, Weibo Zhu, Zhi-Long Chen*, et al. Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. Bioorganic & Medicinal Chemistry, 2016, 24(9): 2023-2031. (SCI, Q2)
國際交流與合作👷🏽♂️：
與英國利物浦大學🧑🏼⚖️、愛爾蘭都柏林大學、愛爾蘭皇家外科沐鸣2、美國新澤西立大學、澳大利亞中昆士蘭大學、克羅地亞魯德爾博斯科維奇研究所→、俄羅斯國家科學中心、南非羅德斯大學等多所大學與研究所有合作關系👂🏽。
講授課程:
新藥研究開發學🩹、基礎有機化學實驗
研究團隊:
團隊成員30余名🤞🏻，含博士助手2名🖐🏼、化學與生物醫學博士後2名、博士碩士研究生二十余名、留學生6名⬇️。
博士後招聘：
招收藥學、化學💏、生物學🧑💻、醫學、材料學等專業博士後🧺。
博士👨🏻🦼➡️、碩士研究生招生：
在化學、生物化學與分子生物學💆🌼、生物與醫藥、生物醫學工程、材料學等專業的博士、碩士點🦌，招收藥學👃、化學🧑🏿🌾、生物學🧑🏿🔬、醫學、材料學等專業背景研究生。
就業前景：
本課題組研究方向就業前景好。
電話🧑🏿🦳：021-67792654👈🏻；E-mail：zhlchen@dhu.edu.cn
Curriculum Vitae
Prof. Zhi-Long Chen
Department of Pharmaceutical Science and Technology,
College of Biology and Medical Engineering
Donghua University. Shanghai, China
Position:
Distinguished Professor of Medicinal Chemistry and Pharmacology.
Director of Department of Pharmaceutical Science and Technology.
Personal Statement:
Zhi-Long Chen got his B.Sc. in 1991 and Ph.D. of Medicinal Chemistry from Second Military Medical University in 1996. He once worked as postdoctoral fellow in Shanghai Institute of Organic Chemistry, Chinese Academy of Science (China); in Central Queensland University (Australia) and the University of Liverpool (England).
He is the vice chair of Shanghai Bio-drugs Association. He also serves as committee member of Shanghai Association of Medicinal Chemistry, Shanghai Association of Pharmacy; committee member of Chinese Association of Laser Medicine; committee member of Shanghai Hospital Pharmacy Association; committee member of Therapeutic Drug Monitoring Research Committee of Shanghai Pharmacological Society; Committee of Shanghai Anti-Cancer Association and Clinical Pharmacy Management Committee of Shanghai Hospital Association; the member of Expert Pool for Shanghai Medical Association; the member of Medical Accident Appraisal and Identification of Abnormal Reactions to Vaccination of Shanghai Medical Association.
Prof. Chen has published more than 340 papers and 5 academic books, applied more than 90 patents. His projects were supported by more than 90 grants from Chinese Government and Shanghai Governments. More than 20 products were prepared and used in factories.
He got the award of “Shanghai Pujiang Talents” in 2008 and “Shanghai outstanding science and technology group leader” in 2014 from Shanghai Science and Technology Bureau.
Research interests:
1. The discovery of new drug based on artificial intelligence (AI) and computer-aided drug design (CADD).
2. The discovery and development of new photosensitizer drugs in photodynamic therapy, and photo-diagnosis to tumor, senile macular degeneration, actinic keratosis, port-wine stains, rheumatoid arthritis.
3. The discovery and development of new targeted drugs, including new anti-tumor drugs，new antihypertensive drugs and new molecular targeted drugs (folic acid, peptides, monoclonal antibodies, etc.).
4. The discovery of targeted nano drug delivery system with multifunction and multimodal effects.
5. The discovery of new drugs from natural products.
6. Studies on the pharmacology, toxicology, pharmacokinetics and mechanism of new drugs.
7. The discovery of new medical imaging agents.
The achievements of new drug discovery:
1. One new photodynamic anti-tumor drug was discovered and was in pre-clinical evaluation.
2. New anti-hypertension drug Intersartan was discovered with high efficiency, long-lasting effect and was in pre-clinical evaluation.
3. As a major participant, new antitumor drug CM-Na was discovered and approved by Chinese SFDA, which is the first radio-sensitizing anti-tumor drug on sale now in the world.
4. As a major participant, new photodynamic drug hermatoporphyrin dimethyl ether (HMME) was discovered and was approved by SFDA to use in clinics. (SFDA approval No. H20120076).
Awards:
1. “Shanghai Pujiang Talents” in 2008 from Shanghai Science and Technology Bureau.
2. “Shanghai outstanding science and technology group leader” in 2014 from Shanghai Science and Technology Bureau.
3. Zhi-Long Chen, Wen-Hui Chen, Yi-Jia Yan, etc. “Studies on the discovery of new photodynamic drugs and reagents, on the fundamental research and application of photodynamic therapy” got the awards from Shanghai Pharmacy Association in 2012.
4. Zhi-Long Chen, Wen-Hui Chen, Yi-Jia Yan, etc. “Studies on the discovery of new photodynamic drugs and reagents, on the fundamental research and application of photodynamic therapy” got the awards from Chinese pharmacy Association in 2013.
5. Xiu-Li Wang, Zhi-Long Chen, Heng Gu, etc. “The key technic innovations and their application of photodynamic therapy in skin diseases” got the award from Chinese Medicine Association in 2017.
6. The first prize of “Innovation and Entrepreneurship Competition of Pinghu city” in 2018.
Grants:
More than 90 projects were supported by Chinese central government and Shanghai city government and other city governments. Recent Grants:
1. Grants from National Natural Science Foundation of China（No. 21372042；30973611；30271534；30070862；29872055👵🏽🖤；21977016, et al）.
2. Grant from “Shanghai outstanding science and technology group leader” programme，（No.15XD1523400）.
3. Grant from “Shanghai Pujiang Talent” programme（No. 06PJ14001）.
4. The key grants from Shanghai government (No. 21430730100；17431902600；15411960400；15431904100；14431906200；14140903500；13431900700, et al)
5. Shanghai International collaboration grant (No. 17430711900; 18430713000, Collaborate with Prof. Davor Margetic, Croatia).
6. Shanghai international collaboration grant (No. 20490740400, collaborate with Prof.Ni Ni Than and Dr. Thin Wut Soe, University of Yangon, Burma）
7. Shanghai international collaboration grant（No. 17430711900, Collaborate with Dr. Nguyen Thi Phuong Anh, Hue University,Vietnam）.
8. Shanghai international collaboration grant (No. 13430722300, Collaborate with Prof. Donal O’Shea, University of Dublin, Ireland）.
9. Shanghai international collaboration grant (No. 21430730100, Collaborate with Dr. X. F. Wu, University of Liverpool, England）.
Publication: more than 340 papers were published.
Some Recent publications:
1. Tabbisa Namulinda, Zhi-Long Chen*, et al. Antibacterial and anticancer activities of green synthesized silver nanoparticles using Photinia glabra fruit extract. Nanomedicine, 2023, 18, (14): 987-1002. (SCI, Q1)
2. Man Yi Li, Zhi Long Chen*, et al. The bromoporphyrins as promising anti-tumor photosensitizers in vitro. Photochemical & Photobiological Sciences, 2023, 22, 427-439. (SCI, Q2)
3. Man Yi Li, Zhi Long Chen*, et al, The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2335-2346. (SCI, Q2)
4. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new fluorinated pyropheophorbide-a derivatives for photodynamic therapy. Dyes and Pigments, 2022, 197, 109932.(SCI, Q1,TOP期刊)
5. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new pyropheophorbide-a derivatives for CAIX-targeted photodynamic therapy. Dyes and Pigments, 2022, 203,110328.(SCI, Q1, TOP期刊).
6. Faiza Sajjad, Zhi-Long Chen*, et al. Incorporation of green emission polymer dots into pyropheophorbide-α enhance the PDT effect and biocompatibility. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102562.（SCI, Q3）
7. Man-Yi Li, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of novel fluorinated hematoporphyrin ether derivatives for photodynamic therapy. Bioorganic Chemistry, 2021, 107, 104528.(SCI, Q1,TOP期刊)
8. Faiza Sajjad, Zhi-Long Chen*, et al. Synthesis and invitro PDT evaluation of red emission polymer dots (R-CPDs) and pyropheophorbide-α conjugates. Scientific Reports. 2021, 11, 10013. (SCI, Q2)
9. Zhuo Wu, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities. Bioorganic Chemistry, 2020, 101, 104042. (SCI, Q1,TOP期刊)
10.Ying-Hua Gao, Zhi-Long Chen*. Synthesis and pharmacological evaluation of chlorin derivatives for photodynamic therapy of cholangiocarcinoma. European Journal of Medicinal Chemistry, 2020,189, 112049.(SCI, Q1,TOP期刊)
11. Ying-Hua Gao, Zhi-Long Chen*, Synthesis and evaluation of novel chlorophyll a derivatives as potent photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2020, 187, 111959.(SCI, Q1,TOP期刊)
12.Ying-Hua Gao, Vanda Lovreković, Zhi-Long Chen*, et al. The photodynamic activities of dimethyl 131-[2-(guanidinyl)ethylamino] chlorin e6 photosensitizers in A549 tumor. European Journal of Medicinal Chemistry, 2019, 177, 144-152. (SCI, Q1,TOP期刊)
13. Zhuo Wu, Yi-Jia Yan, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of AT1 receptor blockers derived from 6-substituted aminocarbonyl benzimidazoles. European Journal of Medicinal Chemistry, 2019,181,111553. (SCI, Q1,TOP期刊)
14. Zhuo Wu, Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of 6-benzoxazole benzimidazole derivatives with anti-hypertension activities. ACS Medicinal Chemistry Letters, 2019, 10, 40 - 43. (SCI, Q2)
15. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity. European Journal of Medicinal Chemistry, 2018, 160, 146-156. (SCI, Q1,TOP期刊)
16. Sonja Srdanovic, Davor Margetic*, Zhi-Long Chen*. The photodynamic activity of 131-[2’-(2-pyridyl)ethylamine] chlorin e6 photosensitizer in human esophageal cancer. Bioorganic & Medicinal Chemistry Letters. 2018, 28(10): 1785-1791. (SCI, Q2)
17. Wei Zhu, Yi-Jia Yan, Zhi-Long Chen*, et al. Synthesis and biological evaluation of 173-dicarboxylethyl pyropheophorbide-a amide derivatives for photodynamic therapy. Bioorganic & Medicinal Chemistry Letters. 2018, 28: 2784-2788. (SCI, Q2)
18. Ping-Yong Liao, Zhi-Long Chen*, et al. Synthesis of 2-morpholinetetraphenylporphyrins and their photodynamic activities. Bioorganic Chemistry, 2017, 71: 299 - 304.(SCI, Q1,TOP期刊)
19. Li Wang, Wei Zhu, Zhi-Long Chen*, et al. Preparation of a chlorophyll derivative and investigation of its photodynamic activities against cholangiocarcinoma. Biomedicine & Pharmacotherapy. 2017, 92: 285-292. (SCI, Q1,TOP期刊)
20. Lei-Lei Bao, Donal F. O’Shea*, Zhi-Long Chen*, et al. In vitro and in vivo evaluation of a pyropheophorbide-a derivative as a potential photosensitizer for age-related macular degeneration. Biomedicine & Pharmacotherapy, 2017, 88: 1220-1226. (SCI, Q1,TOP期刊)
21.Xiaolu Bao, Weibo Zhu, Zhilong Chen*, et al. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists. European Journal of Medicinal Chemistry, 2016, 123,115-127.(SCI, Q1,TOP期刊)
22. Weibo Zhu, Xiaolu Bao, Zhilong Chen*, et al. N-phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2016, 115,161-178.(SCI, Q1,TOP期刊)
23. Xiang-Hua Zhang, Li-Jun Zhang, Zhi-Long Chen*, et al. Photodynamic efficiency of a chlorophyll-a derivative in vitro and in vivo. Biomedicine & Pharmacotherapy, 2016, 81, 265-272. (SCI, Q1,TOP期刊)
24. Li-Jun Zhang, Yi-Jia Yan, Zhi-Long Chen*, et al. Antitumor activity evaluation of meso-tetra (pyrrolidine substituted) pentylporphin-mediated photodynamic therapy in vitro and in vivo. Journal of Photochemistry & Photobiology, B: Biology. 2016, 163:224-231. (SCI, Q1,TOP期刊)
25. Ping-Yong Liao, Ying-Hua Gao, Zhi-Long Chen*, et al. Tetraphenylporphyrin derivatives possessing piperidine group as potential agents for photodynamic therapy. Journal of Photochemistry & Photobiology, B: Biology. 2016, 165: 213-219. (SCI, Q1)
26. Hongyu Tan, Ioannis Houpis, Zhilong Chen*, et al. Olefin preparation via palladium-catalyzed oxidative de-azotative and de-sulfitative internal cross-coupling of sulfonylhydrazones. Organic Letters, 2015,17(14)：3548-3551.(SCI, Q1,TOP期刊)
27. Dan Wu, Zhi-Long Chen and Donal F. O’Shea, et al. Synthesis and assessment of a maleimide functionalized BF2 azadipyrromethene near-infrared fluorochrome. Chemical Communications, 2015, 51(93): 16667-16670.(SCI, Q1,TOP期刊)
28. Li-Jun Zhang, Zhi-Long Chen*, et al. Evaluation of a bacteriochlorin-based photosensitizer’s anti-tumor effect in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2015, 141（11）: 1921-1930. (SCI, Q2)
29. Hongyu Tan, Zhilong Chen*, et al. Palladium-catalyzed coupling of sulfonylhydrazones with heteroaromatic 2-amino-halides (Barluenga Reaction): exploring the electronics of the sulfonylhydrazone. Organic Process Research & Development. 2015, 19(8), 1044-1048. (SCI, Q1)
30. Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and evaluation of novel angiotensin II receptor 1 antagonists with antihypertensive activities. RSC Advances, 2017, 7: 26401-26410. (SCI, Q2)
31. Pingyong Liao, Zhilong Chen*, et al. Synthesis, characterization and biological evaluation of a novel biscarboxymethyl-modified tetraphenylchlorin compound for photodynamic therapy. RSC Advances, 2016, 6: 26186 - 26191. (SCI, Q2)
32. Mengshi Yang, Zhilong Chen, et al. Photodynamic therapy of drug-resistant human colon adenocarcinoma using verteporfin loaded TPGS nanoparticle with tumor homing and penetrating peptide functionalized. RSC Advances, 2016, 6: 100984-100992. (SCI, Q2)
33.Dan Wu, Zhi-long Chen, et al. Strained alkyne substituted near infrared BF2 azadipyrromethene fluorochrome. RSC Advances, 2016, 6: 87373-87379. (SCI, Q2)
34. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of new 5-aminolevulinic acid derivatives as prodrugs of protoporphyrin for photodynamic therapy. Photochemical & Photobiological Sciences. 2017, 16: 1623-1630. (SCI, Q2)
35. Ping-Yong Liao, Xinrong Wang, Zhi-Long Chen*, et al. Synthesis, photophysical properties and biological evaluation of b-alkylaminoporphyrin for photodynamic therapy. Bioorganic & Medicinal Chemistry, 2016, 24(22): 6040-6047. (SCI, Q2)
36. Xiaolu Bao, Weibo Zhu, Zhi-Long Chen*, et al. Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. Bioorganic & Medicinal Chemistry, 2016, 24(9): 2023-2031. (SCI, Q2)
International Collaboration:
We have collaborations with scholars from Ireland, England, Croatia, Russia, Vietnam, Burma, et al which were supported by grants from Chinese central government and Shanghai city government.
Team:
We have a team more than 30 persons, including 2 assistants of PhD, 2 postdoctors, 8 Ph.D students and 14 Master students, 5 international students, 7 technicians.
Labs:
We have more than 300 m2 organic chemistry labs and biological labs in the University and 300 m2 outside the University.
Position Opportunity:
We accept students to our group to finish their Master degree and Ph. D.
Postdoctoral research fellows and visiting scholars are also welcome.
Connecting Information:
E-mail: zlchen1967@qq.com; zhlchen@dhu.edu.cn;
Phone: 0086-21-67792654;
Address🤱🏿：Room 4092🐝，Building 4, 2999 North Songjiang Renmin Road, Songjiang District, Shanghai, China. Postcode: 201620